Electromyography

China Automotive Multimodal Interaction Development Research Report 2023: Multimodal Interaction Application by OEMs and Multimodal Interaction Solutions of Suppliers - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 13, 2024
Autonomous Driving, Vehicles, Automotive, Artificial Intelligence, Technology, Automotive Manufacturing, General Automotive, VoIP, Manufacturing, Head, SIMO, Atmosphere, Emotion, Disinfectant, VOICE, Language, ID, Confusion, System, Human, Research report, Happiness, Air conditioning, Sterilization, Electromyography, Music, Classmates

The "China Automotive Multimodal Interaction Development Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Automotive Multimodal Interaction Development Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • China Automotive Multimodal Interaction Development Research Report, 2023 combs through the interaction modes of mainstream cockpits, the application of interaction modes in key vehicle models launched in 2023, the cockpit interaction solutions of suppliers, and the multimodal interaction fusion trends.
  • In addition, the trunk, windows, music, air conditioning, pull-out/parking and other functions can also be controlled by voice outside the car.
  • Moreover based on voiceprint recognition technology, the system will actively block other disturbing sounds to improve the accuracy of recognition at the driver's seat.

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda

Retrieved on: 
Tuesday, December 12, 2023
Immune system, Electromyography, Disease, Prednisone, Neurological disorder, Pain management, Fatigue, Rituximab, Patient, Gesellschaft mit beschränkter Haftung, EU4, CIDP, Azathioprine, Atrophy, Antibody, Sensation, MRI, Fc receptor, IVIG, Clumsy, Facial muscles, LAS, Neuropathic pain, Diagnosis, Inflammation, Sympathetic nervous system, Pharmaceutical industry, Takeda, Octapharma

LAS VEGAS, Dec. 12, 2023 /PRNewswire/ -- DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight estimates, CIDP in the US showed that males account for the highest number of cases as compared to females in 2022.
  • The promising chronic inflammatory demyelinating polyneuropathy therapies in the pipeline include Panzyga, Efgartigimod, Batoclimab, SAR445088, Nipocalimab, and others.
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes progressive weakness and reduced sensation in the arms and legs.
  • CIDP shows itself through symmetrical weakness in the hands, feet, hips, and shoulders, gradually worsening over a minimum of two months.

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda

Retrieved on: 
Tuesday, December 12, 2023
Immune system, Electromyography, Disease, Prednisone, Neurological disorder, Pain management, Fatigue, Rituximab, Patient, Gesellschaft mit beschränkter Haftung, EU4, CIDP, Azathioprine, Atrophy, Antibody, Sensation, MRI, Fc receptor, IVIG, Clumsy, Facial muscles, LAS, Neuropathic pain, Diagnosis, Inflammation, Sympathetic nervous system, Pharmaceutical industry, Takeda, Octapharma

LAS VEGAS, Dec. 12, 2023 /PRNewswire/ -- DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight estimates, CIDP in the US showed that males account for the highest number of cases as compared to females in 2022.
  • The promising chronic inflammatory demyelinating polyneuropathy therapies in the pipeline include Panzyga, Efgartigimod, Batoclimab, SAR445088, Nipocalimab, and others.
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes progressive weakness and reduced sensation in the arms and legs.
  • CIDP shows itself through symmetrical weakness in the hands, feet, hips, and shoulders, gradually worsening over a minimum of two months.

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Retrieved on: 
Wednesday, October 25, 2023
IH, BRT, Wakefulness, Sleep, Cataplexy, IND, NT2, Human, Congress, Narcolepsy, Electromyography, DTA, Idiopathic hypersomnia, OX2R, OX1R, PK, EC50, EMG, EEG, CHO, Patient, CNTA, Pharmaceutical industry, Aroma compound, Surat Bus Rapid Transit System, NT1

BOSTON and LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced a robust set of new preclinical data from in vivo and in vitro studies of its investigational, novel orexin receptor 2 (OX2R) agonist, ORX750, that support its potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders.

Key Points: 
  • “The preclinical data showed ORX750 achieved maximal wake times and suppressed cataplexy at 0.1 mg/kg, the lowest oral dose tested in the DTA mouse model.
  • Notably, this activity was observed in both the DTA and Atax mouse models that recapitulate NT1 symptoms in humans.
  • Fluorescent imaging plate reader (FLIPR) assay with Chinese hamster ovary (CHO) cells stably expressing recombinant human OX1R or OX2R; OXA EC50 at hOX2R = 0.035 nM.
  • As measured by electroencephalogram (EEG) and electromyogram (EMG) with concurrent video in DTA and Atax mouse models.

WiMi Developed a Hybrid Bio-Signal-Based Brain-Computer Interface

Retrieved on: 
Monday, October 23, 2023
Cloud, Intelligence, Relaxation, Feedback, Cerebral cortex, Eye, Neuron, WIMI, Electromyography, Acquisition, BCI, Electroencephalography, Light, Research, Muscle contraction, Artificial intelligence, Interface (computing), Holography, Periodic limb movement disorder, Virtual reality, Infrared spectroscopy, Machine learning, EMG, Scalp, HBS, Electrooculography, Classification, Brain, Noise, Algorithm, EOG, EEG, AR, Ophthalmoscopy, Augmented reality, Electrode, Medical imaging, Instrumentation

BEIJING, Oct. 23, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that WiMi has developed a hybrid bios-signal-based brain-computer interface (HBS-BCI) that is rapidly gaining prominence.

Key Points: 
  • BEIJING, Oct. 23, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that WiMi has developed a hybrid bios-signal-based brain-computer interface (HBS-BCI) that is rapidly gaining prominence.
  • As a company focused on innovation and technology, WiMi is committed to providing advanced solutions that improve the way people interact with technology.
  • Paradigm design and task setup determine the specific activities or tasks to be accomplished by the user in the brain-computer interface task.
  • In addition to the basic application of HBS-BCI technology, WiMi will further research and develop HBS-BCI to promote its real-time application in daily life scenarios.

IEEE EMBS Welcomes Professor He (Helen) Huang as Editor-in-Chief of TNSRE Journal

Retrieved on: 
Friday, October 6, 2023
Software, Research, Internet, Hardware, Data Management, Technology, Health Technology, Science, Engineering, Biotechnology, Health, Other Science, Manufacturing, Rehabilitation, Amputation, Organization, BME, Institute of Electrical and Electronics Engineers, State university system, University, Computation and Neural Systems, Movement, NIDRR, NSF, Robotics, Disability, AIMBE, Arizona State University, Growth, Parliament (Joint Departments) Act 2007, Biomedicine, NIDILRR, ASA, Biomedical engineering, Consumer electronics, IEEE, Electromyography, Medicine

IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS) , today announced the incoming appointment of Professor He (Helen) Huang as editor-in-chief of IEEE Transactions on Neural Systems and Rehabilitation Engineering (TNSRE).

Key Points: 
  • IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS) , today announced the incoming appointment of Professor He (Helen) Huang as editor-in-chief of IEEE Transactions on Neural Systems and Rehabilitation Engineering (TNSRE).
  • Dr. Huang’s research focuses on neural-machine interfaces, prosthetic and exoskeleton control, human-robot interaction, and human movement control.
  • “As we look ahead to Dr. Huang's stewardship of IEEE TNSRE, we anticipate an exciting chapter of growth, innovation, and impactful research,” said Paul Sajda, Ph.D., president of the IEEE EMBS.
  • I look forward to working with the editors and the team at IEEE TNSRE in accomplishing the missions of the journal and the society, and providing quality, field-leading research to our peers.”

Brooks Rehabilitation, Mayo Clinic to Collaborate on New Comprehensive Physical Medicine & Rehabilitation Residency Program

Retrieved on: 
Monday, June 26, 2023
Medicine, Mayo Clinic, PM, Accreditation, Tetraplegia, Stroke, Pediatrics, Hospital, Graduate medical education, Rehabilitation, PM&R, Electromyography, Student, U.S. News & World Report, National Resident Matching Program, Association of American Medical Colleges, Patient, Internal medicine, Accreditation Council, News, Health insurance, Newsweek

The Mayo Clinic PM&R Residency Program in Collaboration with Brooks Rehabilitation is a four-year categorical program offering an opportunity to train in a world-class medical institution while gaining hands-on experience in one of the top rehabilitation hospitals in the region.

Key Points: 
  • The Mayo Clinic PM&R Residency Program in Collaboration with Brooks Rehabilitation is a four-year categorical program offering an opportunity to train in a world-class medical institution while gaining hands-on experience in one of the top rehabilitation hospitals in the region.
  • Residents will complete their first year of training in the Internal Medicine Preliminary Year Program at Mayo Clinic.
  • Training at Mayo Clinic and Brooks Rehabilitation allows residents to learn from some of the field's most respected clinicians and researchers.
  • "We are excited to collaborate with Brooks Rehabilitation to launch this new PM&R Residency Program in Florida," said James Atchison, D.O., chair of PM&R at Mayo Clinic and PM&R residency program director.

WiMi to Design A Hybrid BCI-Based Humanoid Control System

Retrieved on: 
Friday, June 23, 2023
Cloud, Holography, Suitability analysis, Augmented reality, Evoked potential, BCI, WIMI, Disability, EOG, NIRS, EMG, Support, SSVEP, Brain, Rehabilitation, Attention, Research, ERD, SVM, Random forest, Signal, Acquisition, Machine learning, EEG, Algorithm, Support vector machine, NIR, AR, Medical imaging, Instrumentation, Satellite navigation device, Video game, Electromyography, Electrooculography

BEIJING, June 23, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it had made significant progress in the field by developing a humanoid control system based on hybrid signals BCI.

Key Points: 
  • BEIJING, June 23, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it had made significant progress in the field by developing a humanoid control system based on hybrid signals BCI.
  • Finally, the decoding results are mapped to the humanoid robot control to realize the power of the humanoid robot.
  • Finally, the humanoid control system based on hybrid BCI technology can achieve more natural and precise control, which can be applied to many fields, such as the robot and disabled assistance.
  • The humanoid control system also has good applicability and operability and can be adapted to the needs and characteristics of different users.

Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000

Retrieved on: 
Wednesday, June 7, 2023
Good, ED95, Bromide, Arm, Plasma protein binding, Clinical trial, EMG, NMB, Electromyography, MD, Patient, Safety, Anesthesiology, Pharmaceutical industry, Anesthesia

Additional analyses of electromyography (EMG) of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium.

Key Points: 
  • Additional analyses of electromyography (EMG) of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium.
  • The BX1000 Phase 2 surgery trial was a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a completed clinical trial of 80 adult patients who had elective surgery utilizing total intravenous anesthesia.
  • A total of 81 patients were randomized to the four treatment groups.
  • Additionally, the clinical trial evaluated the safety and tolerability profile of BX1000 and rocuronium in this patient population.

Gwangju Institute of Science and Technology Researchers Develop Injectable Bioelectrodes with Tunable Lifetimes

Retrieved on: 
Thursday, May 11, 2023
Tissue, GIST, Gel, DSM-IV codes, ICH, Gwangju Institute of Science and Technology, Electromyography, Electrode, Small, Fish hydrolysate, Prepolymer, Skin, Medical device, Silk

GWANGJU, South Korea, May 11, 2023 /PRNewswire/ -- Implantable bioelectrodes are electronic devices that can monitor or stimulate biological activity by transmitting signals to and from living biological systems. Such devices can be fabricated using various materials and techniques. But, because of their intimate contact and interactions with living tissues, selection of the right material for performance and biocompatibility is crucial. In recent times, conductible hydrogels have attracted great attention as bioelectrode materials owing to their flexibility, compatibility, and excellent interaction ability. However, the absence of injectability and degradability in conventional conductive hydrogels limits their convenience of use and performance in biological systems.

Key Points: 
  • In recent times, conductible hydrogels have attracted great attention as bioelectrode materials owing to their flexibility, compatibility, and excellent interaction ability.
  • However, the absence of injectability and degradability in conventional conductive hydrogels limits their convenience of use and performance in biological systems.
  • Against this backdrop, researchers from Korea have now developed graphene-based conductive hydrogels possessing injectability and tunable degradability, furthering the design and development of advanced bioelectrodes.
  • The study was led by Professor Jae Young Lee from Gwangju Institute of Science and Technology (GIST) and was published in the Small journal on 24 February 2023.